Role of hypercoagulability and hypofibrinolysis in the progression of hepatic fibrosis

Role of hypercoagulability and hypofibrinolysis in the progression of hepatic fibrosis - Coagulation and Fibrosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34971

Enrollment

292

Registered

2010-10-15

Start date

2011-04-20

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic fibrosis scarring of the liver

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. All participants of the Rotterdam Study (cohorts RS I-5, RS II-3 and RS III-1). - 1a. TE values >12,5 kPa in the absence of steatosis will be considered as presence of advanced fibrosis. TE values >10,5 kPa in the presence of steatosis will be considered as presence of advanced fibrosis (cases). - 1b. TE values =18 3. All subjects must have provided written informed consent.

Exclusion criteria

Exclusion criteria: a. Subjects with unreliable Fibroscan and/or US-examination, as evaluated by the executing technician. b. No informed consent c. Subjects with decompensated cirrhosis

Design outcomes

Primary

Measure	Time frame
Prevalence of prothrombotic risk factors in patients with advanced fibrosis compared to controls with no or mild fibrosis.	—

Secondary

Measure	Time frame
-	—

Countries

Netherlands

Outcome results